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ABSTRACT Low-dose primaquine is recommended to prevent Plasmodium falcipa-
rum malaria transmission in areas threatened by artemisinin resistance and areas
aiming for malaria elimination. Community treatment campaigns with artemisinin-
based combination therapy in combination with the gametocytocidal primaquine
dose target all age groups, but no studies thus far have assessed the pharmacoki-
netics of this gametocytocidal drug in African children. We recruited 40 children par-
ticipating in a primaquine efﬁcacy trial in Burkina Faso to study primaquine pharma-
cokinetics. These children received artemether-lumefantrine and either a 0.25- or a
0.40-mg/kg primaquine dose. Seven blood samples were collected from each partici-
pant for primaquine and carboxy-primaquine plasma levels determinations: one
sample was collected before primaquine administration and six after primaquine
administration according to partially overlapping sampling schedules. Physiological
population pharmacokinetic modeling was used to assess the impact of weight, age,
and CYP2D6 genotype on primaquine and carboxy-primaquine pharmacokinetics.
Despite linear weight normalized dosing, the areas under the plasma concentration-time
curves and the peak concentrations for both primaquine and carboxy-primaquine in-
creased with age and body weight. Children who were CYP2D6 poor metabolizers
had higher levels of the parent compound, indicating a lower primaquine CYP2D6-
mediated metabolism. Our data indicate that primaquine and carboxy-primaquine
pharmacokinetics are inﬂuenced by age, weight, and CYP2D6 genotype and suggest
that dosing strategies may have to be reconsidered to maximize the transmission-
blocking properties of primaquine. (This study has been registered at ClinicalTrials.gov
under registration no. NCT01935882.)
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Since 2012, the World Health Organization (WHO) recommends the use of a single0.25-mg/kg dose of primaquine (PQ) in combination with standard artemisinin-
based combination therapy (ACT) for the treatment of Plasmodium falciparum malaria
in elimination and resistance containment settings (1). The rationale for using PQ is to
prevent transmission of malaria to mosquitoes since it is the only currently available
antimalarial that accelerates the clearance of mature gametocytes post-ACT (2). Several
recent trials assessed the efﬁcacy of the WHO-recommended dose and concluded that
it reduces gametocyte carriage compared to ACT alone and effectively prevents
transmission in mosquito infection experiments (3–6). In addition to its use to prevent
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P. falciparum transmission as a single-dose treatment, PQ has been used for decades in
multiple-dose regimens to clear Plasmodium vivax hypnozoites (7, 8).
The parent compound is not responsible for PQ effects on P. vivax hypnozoites (9)
and P. falciparum gametocytes (10), and the drug-metabolizing cytochrome P450 2D6
(CYP2D6) enzyme has been implicated in the formation of unknown active metabolites
that are responsible for the pharmacological effect of PQ (9, 11–13). In mice, knocking
out the CYP2D locus can reduce the metabolism of PQ into its active metabolite against
Plasmodium berghei (11) and increase the area under the plasma concentration-time
curve for PQ (14). The gene coding for this enzyme (CYP2D6) is hypervariable in
humans, and there is limited knowledge on the effects of the variation at this locus on
the pharmacokinetics of PQ in humans (9). Early pharmacokinetic studies of PQ in
adults (15–19) identiﬁed the main PQ metabolite, carboxy-PQ (C-PQ), which is slowly
eliminated and is present at plasma concentrations up to 10 times higher than those
of its parent compound (16). C-PQ is produced by monoamine oxidase (MAO)-A (12), an
enzyme involved in drug metabolism in the liver (20), and indirect evidence (9, 21)
suggests that it is not the active metabolite against malaria parasites or one of its
precursors.
To date, there are only limited PQ pharmacokinetic data (16–18, 22). This is partic-
ularly evident for single low-dose PQ and for pharmacokinetic data in children: only one
study, undertaken in Papua New Guinea and using single PQ doses of 0.5 or 1.0 mg/kg,
recruited children (22). The difﬁculty to accurately dose children by extrapolating
dosing schemes from adults (23–26) was previously illustrated for the antimalarials
sulfadoxine-pyrimethamine and dihydroartemisinin-piperaquine (27). Since children
are frequently infectious to mosquitoes (28) and comprise an important part of the
human infectious reservoir for malaria (29), data on single low-dose PQ pharmacoki-
netics in children are highly needed for the planning of community treatment cam-
paigns with PQ to reduce P. falciparum transmission. To identify factors that impact PQ
pharmacokinetics in children, we performed a pharmacokinetic study of PQ in the
largest pediatric population examined thus far.
RESULTS
Study population. A total of 40 afebrile children aged 2 to 14 years who received
a single low dose (0.25 or 0.40 mg/kg) of PQ on the ﬁnal day of a six-dose artemether-
lumefantrine (AL) regimen were included in this study. Of these 40, 37 had patent
asexual-stage P. falciparum parasites at enrollment (median and interquartile range
[IQR], 1,252 parasites/l [578 to 2,503 parasites/l]). The median (IQR) hemoglobin
level at enrollment was 11.6 g/dl (10.8 to 12.5 g/dl) and similar in the two study
arms. Table 1 summarizes the demographics and baseline laboratory results for these
40 children.
TABLE 1 Baseline characteristics
Parameter
Study arm (PQ dose)
0.25 mg/kg 0.40 mg/kg
No. of participants 20 20
Gender (% female) 55 60
Median (IQR)
Age (yrs) 8 (6–10) 10 (6.5–12)
Body wt (kg) 19.8 (16.2–26.3) 24.9 (15.9–31.6)
Ht (cm) 118 (104–133.5) 129 (104–144.5)
Temp (°C) 36.6 (36.4–37.0) 36.7 (36.1–36.9)
No. of asexual parasites/l 991 (635.5–2,066.5) 1,188 (284.5–3,340)
Hemoglobin (g/dl)a 11.4 (10.6–12.5) 11.9 (11.1–12.7)
Alanine transaminase (U/liter) 22.5 (17.5–34.5) 22 (17–29)
Aspartate transaminase (U/liter) 38 (32–46) 36 (27–41)
Total bilirubin (mol/liter) 7.4 (5.4–9.9) 10.8 (8–13.8)
Creatinine (mol/liter) 37.8 (35.5–40.8) 38.4 (32.7–45.2)
aHemoglobin levels were measured by using Hemocue.
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CYP2D6 genotyping. CYP2D6 genotyping was successful for 36/40 children. For
3/40 participants no samples were available for genotyping, and for one the genotyp-
ing was inconclusive. Allele frequencies are presented in Table S2 in the supplemental
material. Of these 36 study subjects, 1/36 (2.8%), 10/36 (27.8%), 22/36 (61.1%), and 3/36
(8.3%) were classiﬁed as poor metabolizers (PM; activity score [AS] of 0), intermediate
metabolizers (IM; AS of 0.5 or 1.0), extensive or normal metabolizers (EM; AS of 1.5 or
2.0), and ultrarapid metabolizers (UM; AS of 3.0), respectively (30, 31).
Pharmacokinetics. A total of 274 plasma samples were collected. Two of the 40
children were excluded from the pharmacokinetic analysis because it was not possible
to determine PQ and C-PQ levels in their samples due to inadequate sample volume.
The raw pharmacokinetic data of PQ and C-PQ per dose group are depicted in Fig. 1.
As observed, PQ was rapidly absorbed, and the plasma C-PQ concentrations were
generally higher than the plasma PQ concentrations. Overall, the pharmacokinetics of
the parent compound and of its main plasma metabolite presented substantial inter-
individual variation.
A physiological pharmacokinetic model was developed to estimate pharmacokinetic
parameters for both PQ and C-PQ (Fig. 2). First-order kinetics with two absorption
transit compartments and one compartment disposition for PQ and C-PQ ﬁt the
observed plasma levels well. PQ was rapidly absorbed with a mean absorption time of
0.706 h (relative standard error [coefﬁcient of variation], 12%). Although allometric
clearance appeared to explain most weight-related variability in pharmacokinetics,
overprediction of plasma PQ and C-PQ concentrations was observed in the youngest
children of our study population. This resulted in higher than expected estimates for
apparent volume of distribution and apparent clearance in these children. This phe-
nomenon may be explained by a reduced relative bioavailability at younger age.
FIG 1 PQ and C-PQ plasma levels (y axes) after PQ administration (x axes). In panels A and C, PQ levels are presented for participants who
received the 0.25- and 0.40-mg/kg PQ doses, respectively. In panels B and D, the C-PQ levels are presented for the 0.25- and 0.40-mg/kg
PQ study arms, respectively. Assay results for all samples collected after PQ administration, including those with PQ or C-PQ levels below
the limit of detection (i.e., with assigned level of 0 ng/ml), are presented.
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Therefore, maturation of relative bioavailability (F) with age (i.e., the increase in
bioavailability with age) was described by an Emax model according to the following
formula: F  age/(age  F50), where F50 is the age in years at which the relative
bioavailability is 50% that of the mature value. F50 was estimated to be 4.27 years
(relative standard error, 44%), explained all observed interindividual variability in
relative bioavailability, signiﬁcantly (P  0.001) improved the model ﬁt, and was
therefore retained in the model. In addition to apparent age-dependent bioavailability,
the inclusion of CYP2D6-mediated clearance of PQ, assumed to be linearly related to
the CYP2D6 activity score, signiﬁcantly improved model ﬁt (P  0.001) and was also
retained in the ﬁnal model. Diagnostic prediction-corrected visual checks of the model
are shown in Fig. 3 and additional goodness-of-ﬁt assessments are presented in Fig. S1
and S2 in the supplemental material. Estimated model parameters and their variability
are presented in Table 2.
The model-derived median (range) area under the concentration-time curve (AUC),
the maximum concentration (Cmax), and the time of Cmax (Tmax) for PQ were 600.26
h·ng/ml (259.87 to 3,315.40 h·ng/ml), 68.42 ng/ml (20.21 to 391.16 ng/ml), and 1.59 h
(0.96 to 2.12 h), respectively, and are in agreement with previous studies (18); for C-PQ
these values were 3,468.35 (962.05 to 10,506) h·ng/ml, 147.23 (25.61 to 403.95) ng/ml
and 6.80 (2.73 to 16.03) h, respectively. The 0.40-mg/kg PQ dose was associated with a
higher AUC and Cmax compared to the 0.25-mg/kg dose (Table 3), although there was
substantial variation within each study arm: Cmax estimates included values that were
Depot
k40
PQ
Absorption transit compartments
Liver
k46
k64
C‐PQ
k45
k50
k12 k23 k34
FIG 2 Schematic representation of the model. The mass transport of this model can be described with
the following rate constants: k12  3/MAT, k23  3/MAT, k34  3/MAT, k40  CLH,CYP2D6/VL, k45 
CLH,MAO/VL, k50  CLCPQ/VCPQ, k46  [QH (1  EH)]/VL, and k64  QH/VPQ.
FIG 3 Prediction-corrected visual predictive check of observed data. The left and right panels depict the prediction-
corrected visual predictive checks for PQ and C-PQ, respectively, based on 1,000 simulations. Prediction-corrected
simulated (shaded areas) and observed (circles and lines) PQ and C-PQ concentrations are presented over time (h;
y axes). The thick red line connects the observed median values per bin. The dotted red lines connect the 5th and
95th percentiles of the observations. The light blue areas are the 95% conﬁdence interval of the 5th and 95th
percentiles, and the light red area indicates the conﬁdence interval of the median.
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6 to 10 times higher than the lowest model-derived Cmax in each study arm; a similar
pattern was observed for the AUC.
Host characteristics inﬂuencing PQ pharmacokinetics. PQ doses are linearly
scaled with body weight. To assess whether this approach is appropriate, we analyzed
plasma PQ and C-PQ concentrations by weight. In Fig. 4, the distribution of model-
derived AUC values by weight and PQ dose is presented. For each dose, despite linear
dose extrapolation based on weight, AUC estimates of PQ and C-PQ were positively
correlated with body weight. A similar pattern was observed when analyzing the
relationship between AUC values and age (see Fig. S3 in the supplemental material).
CYP2D6 AS was an important determinant of PQ and C-PQ concentrations. In Fig. 5,
typical plasma PQ and C-PQ concentration-time curves for children aged 2 (body
weight, 12 kg) and 14 (body weight, 40 kg) years old and with different CYP2D6
metabolizer status are presented. Toddlers who are IM have particularly low plasma
levels of PQ compared to schoolchildren with PM status.
DISCUSSION
The use of PQ to prevent P. falciparum transmission may support malaria elimination
activities and efforts to contain artemisinin resistance. Understanding PQ pharmacoki-
netics is important to optimize a dosing regimen aimed at clearing gametocytes and
reducing infectivity to mosquitoes. We performed the ﬁrst PQ pharmacokinetic study in
African children and observed that age, body weight, and CYP2D6 genotype inﬂuenced
PQ and C-PQ plasma levels: younger children and children with lower body weight
have lower levels of PQ and C-PQ, whereas poor CYP2D6 metabolizers have higher
levels of PQ. These ﬁndings indicate that linear weight-based dosing may be subopti-
mal to achieve efﬁcacious PQ concentrations.
TABLE 2 Pharmacokinetic model parametersa
Parameter Estimate
Relative SE of
estimate (% CV) Shrinkage (%)
Mean absorption time (h) 0.706 h 12
PQ vol of distribution (VPQ) (70 kg), liters 127 20
VPQ interindividual variability (%) 82.9 38 12.2
C-PQ vol of distribution (VCPQ) (70 kg), liters 21.7 39
CLint,MAO (70 kg), liters/h 7.35 41
CLint,MAO interindividual variability (%) 65.3 33 13.1
CLint,CYP2D6,pop (70 kg), liters/h 6.70 69
CLCPQ (70 kg), liters/h 1.50 35
F50 (yrs) 4.27 44
Residual error: PQ
Proportional (%) 32.7 42 19.5
Additive (ng/ml) 2*
Residual error: CPQ
Proportional (%) 45.2 20 21.6
Additive (ng/ml) 2*
aAll ﬂow and volume parameters were allometrically scaled to a body weight of 70 kg with an allometric
exponent of 0.75 for ﬂow parameters and an exponent of 1 for volume parameters. CV, coefﬁcient of
variation. *, values ﬁxed during modeling.
TABLE 3Model-derived pharmacokinetic parameters for PQ and C-PQ in African children receiving a single PQ dose of 0.25 (n  18) or
0.40 (n  20) mg/kg
Parameter
Median (range)
0.25 mg/kg (PQ dose) 0.40 mg/kg (PQ dose)
PQ C-PQ PQ C-PQ
Tmax (h) 1.6 (1.2–1.9) 7.1 (4.3–10.1) 1.6 (1.0–2.1) 6.6 (2.7–16.0)
Cmax (ng/ml) 50.2 (20.2–138.7) 108.3 (25.6–240.2) 88.9 (24.4–391.2) 196.8 (29.3–404.0)
AUC0–∞ (h·ng/ml) 450.4 (259.9–875.9) 2,912.3 (962.1–5,076.3) 730.7 (334.2–3,315.4) 5,091.7 (1,075.0–10,506)
Primaquine Pharmacokinetics in African Children Antimicrobial Agents and Chemotherapy
May 2017 Volume 61 Issue 5 e02590-16 aac.asm.org 5
 o
n
 July 23, 2017 by TERKKO
 NATIO
NAL LIBRARY O
F HEALTH SCIENCES
http://aac.asm
.org/
D
ow
nloaded from
 
Since the 1980s several PQ pharmacokinetic studies have been performed; however,
only one of these studies enrolled children (22). This is the ﬁrst PQ pharmacokinetic
study recruiting African children, a group that may represent 28.4 to 51.8% of all
individuals capable of infecting mosquitoes in some endemic areas (28) and thus are an
important target population for PQ treatment. Our analysis generated several insights
into PQ pharmacokinetics in this age group. First, both age and weight explain
variability in PQ pharmacokinetics in children and show a nonlinear relationship with
PQ exposure. This is illustrated by the clear relationship between age and PQ exposure
despite linear dose normalization based on weight. Therefore, linear dosing based on
total body weight is inappropriate to obtain similar drug exposure in children as in
adults, conﬁrming earlier ﬁndings that (nonlinear) allometric scaling of pharmacokinet-
ics of PQ accounted for the observed variability in Papua New Guinean children (22).
However, this study did not report an age effect on bioavailability as observed by us.
This might be explained by the fact that in our study PQ was administered using 1
FIG 4 Area under the plasma concentration-time curves for PQ (left panel) and C-PQ (right panel) by weight
(x axes).
FIG 5 Effect of age and CYP2D6 activity score (AS) on PQ and C-PQ plasma concentrations over time after
a 0.25-mg/kg single dose of PQ. Panels A and B, respectively, show the effects of age on PQ and C-PQ
concentrations over time in two hypothetical children of different ages (2-year-old, 12-kg body weight;
14-year-old, 40-kg body weight), with a CYP2D6 AS  1.0. Panels C and D, respectively, show the effects
of genetically determined CYP2D6 AS in four hypothetical 14-year-old children on the PQ and C-PQ
concentration over time. The values used to construct curves are model derived.
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mg/ml solutions, which allows for more accurate dosing than tablet-based regimens,
and that our study population covered a wider age range (2 to 14 years) compared to
the previous study in Papua New Guinea (6 to 10 years). The physiological cause of the
observed maturation of bioavailability remains unclear. This phenomenon is not un-
common in pediatric pharmacokinetics: for example, the bioavailability of the liquid
formulation of the antiretroviral drug efavirenz also matured with age in young children
(32). Potential causes could be age-related changes in gastrointestinal motility, pH,
or prehepatic expression of metabolic enzymes or transporters, possibly resulting in
increased absorptive capacity with age (33, 34). These ﬁndings should be conﬁrmed
prospectively with additional PQ pharmacokinetic and pharmacodynamic studies in
pediatric, as well as adult populations, to assess the effect of weight and age on
PQ-related pharmacokinetics, as well as gametocyte clearance, transmission reduction,
and toxicity.
Another important ﬁnding of our study is that CYP2D6 genotype inﬂuences PQ
pharmacokinetics (14). Initial PQ concentrations are affected by the CYP2D6 genotype
since CYP2D6-mediated metabolism occurs both systemically and presystemically. The
inﬂuence of CYP2D6 metabolizer status on PQ efﬁcacy was previously shown by an
increased P. vivax relapse rate in individuals with CYP2D6 PM and IM genotypes (9).
Individuals with higher relapse rates, presumably because of an inability to clear P. vivax
hypnozoites, had a signiﬁcantly higher PQ AUC than extensive metabolizers but no
differences in C-PQ pharmacokinetics parameters, which suggests that CYP2D6 activity
is a rate-limiting step in the formation of active metabolite(s) against P. vivax hypno-
zoites (9, 11). It has been hypothesized that unknown metabolites formed through
CYP2D6 are also responsible for the effect of PQ on P. falciparum transmission; however,
direct evidence for this is lacking, and the available ﬁeld studies with comprehensive
CYP2D6 data are too small to assess the effect of CYP2D6 metabolizer status on
gametocytemia and transmission potential after single low-dose PQ. CYP2D6-related
differences in PQ transmission blocking efﬁcacy would be particularly relevant in
malaria elimination settings, where mass drug administration are used to accelerate
transmission interruption: CYP2D6 poor metabolizers might remain infectious for lon-
ger periods of time after PQ administration compared to individuals with other CYP2D6
genotypes and could represent a source of residual malaria transmission in these areas,
depending on the frequency of alleles linked to this phenotype in the population.
Since PQ metabolism is considered essential to its effect on P. falciparum transmis-
sion (10), one may argue that exposure to the parent drug (PQ) is not important.
However, since the formation of active metabolites depends on the presence of the
parent drug, one should aim for an adequate initial exposure of PQ. Our ﬁndings
suggest that age, body weight, and CYP2D6 genotype can all inﬂuence PQ levels and
consequently may determine the levels of active metabolites generated. These obser-
vations and the fact that currently available PQ tablet sizes are not optimal for pediatric
dosing, posing further challenges in achieving the target PQ dose in children, indicate
that PQ dosing strategies may have to be reconsidered. The therapeutic range over
which PQ prevents malaria transmission is currently not well established but may
include doses lower than the WHO-recommended PQ dose of 0.25 mg/kg (5). PQ
efﬁcacy and added value over ACT alone may also depend on the ACT used (4, 5, 35).
The gametocytocidal and transmission blocking effects of AL are superior to that of
dihydroartemisinin-piperaquine, but there are concerns for drug-drug interactions
between AL and PQ. Indeed, although artemether does not inﬂuence PQ metabolism
(36), lumefantrine inhibits CYP2D6 in vitro (37, 38). In our study, although participants
were treated with lumefantrine, we found that the CYP2D6 activity score explained the
variability in PQ pharmacokinetics, indicating that if CYP2D6 was indeed inhibited by
lumefantrine, this inhibition was incomplete at the time of PQ administration. Since AL
alone is by far the most widely used ACT, our CYP2D6-related ﬁndings are of immediate
relevance for ACT-PQ policies, and our ﬁndings of age-dependent exposure to PQ and
C-PQ are likely to be independent of the type of ACT-PQ combination.
PQ is considered a valuable tool to support malaria elimination efforts. Whether it
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is deployed during mass drug administration campaigns, when all individuals in a
community receive treatment, or during treatment of symptomatic falciparum malaria
episodes, a substantial proportion of PQ doses are likely to be given to young children.
Age-related changes in PQ pharmacokinetics, such as the maturation of bioavailability
or a nonlinear change in clearance with weight, indicate that dose extrapolation from
adult regimens based solely and linearly on weight may not be an optimal approach.
A limitation of our study is that the studied population was relatively small and did not
include subjects outside the 2- to 14-year range. Extrapolation of our ﬁndings outside
this range should, therefore, be performed with caution. Future studies relating plasma
concentrations of PQ and its (active) metabolites are needed to quantify the implica-
tions of our ﬁndings for the ability to prevent P. falciparum transmission by PQ
treatment and to inform better dosing strategies.
MATERIALS AND METHODS
Study site, approvals, and patients. A randomized placebo-controlled trial to assess the effect of
low-dose PQ on malaria transmission was undertaken in Balonghin, a village with endemic malaria
transmission in Burkina Faso. Study procedures and results were described in detail elsewhere (4). Brieﬂy,
parasitemic children aged between 2 and 15 years without malaria symptoms (no measured fever,
reported fever, or anemia) and with normal glucose-6-phosphate dehydrogenase enzyme activity were
recruited and treated with AL alone, with AL and a 0.25-mg/kg PQ dose, or with AL and a 0.40-mg/kg PQ
dose. PQ dosing was achieved by crushing a 15-mg PQ tablet and preparing 1-mg/ml solution by
dissolving the crushed tablet in 15 ml of water. This allowed precise dosing: the mean difference
between the actual dose given and the assigned dose was 0.004 mg (95% conﬁdence interval 0.006
to 0.001 mg) of PQ/kg of body weight for participants included in this pharmacokinetic study. AL was
given twice daily over 3 days, and PQ or placebo was administered with the ﬁfth AL dose. A subset of
study subjects not included in mosquito membrane feeding experiments was invited to participate in the
pharmacokinetic study. To minimize the number of blood samples taken per participant while maximiz-
ing the number of time points with information on PQ and C-PQ levels, partially overlapping sampling
schedules were designed, and sampling times were sequentially allocated to participants. The exact time
when each blood sample was collected was recorded and used in pharmacokinetic analyses. A total of
seven 1.5- to 2-ml venous blood samples were collected for each study subject: one sample before PQ
or placebo administration, four in the ﬁrst 12 h following this dose, and two between 24 and 72 h. All
samples were centrifuged within 2 h of collection, and plasma was subsequently stored at 80°C. Forty
participants, 20 from each PQ study arm, had PQ and C-PQ plasma levels quantiﬁed and were included
in this analysis.
The study was registered at ClinicalTrials.gov (reference number NCT01935882). Written informed
consent was obtained for participation in the pharmacokinetics sampling. The clinical trial received ethics
approval from the London School of Hygiene and Tropical Medicine ethics committee (reference 6274)
and the Comité d’Ethique pour la Recherche en Santé (Ministère de la Santé du Burkina Faso; reference
2012-10-78).
Quantiﬁcation of PQ and C-PQ plasma levels. PQ and C-PQ levels were determined by liquid
chromatography-mass spectrometry (LC-MS) as previously described (39). The system consisted of a
Shimadzu LCMS-2010A mass spectrometer operated using electrospray ionization (ESI) in positive ion
detection mode. Data were collected in the selected ion monitoring mode at 325.35 m/z for quinine
(internal standard; retention time, 3.7 min), 260.30 m/z for PQ (retention time, 5 min), and 275.25 m/z for
C-PQ (retention time, 8 min). The analytical column was a Phenomenex Synergi Polar RP (150 by 2 mm,
4 m), preceded by a Polar RP security guard column (2 by 4 mm; Phenomenex, Torrance, CA). The
standard curve ranged from 4 to 1,000 ng/ml, with a lower limit of quantitation of 4 ng/ml and a lower
level of detection of 1 ng/ml. All control values were within 15% of their nominal value.
CYP2D6 genotyping. EDTA-anticoagulated venous blood and/or saliva samples collected with an
Oragene kit (OG-500 or OG-575) were used as sources of human genomic DNA for CYP2D6 genotyping.
DNA was extracted using a MagNAPure LC automated extractor and extraction kits for large volume
samples according to the manufacturer’s instructions. DNA concentration was measured ﬂuorometrically
using a Qubit ﬂuorometer and the accompanying high-sensitivity kit. Samples were diluted according to
the manufacturer’s instructions for assays determining copy number variation (CNV) and for preampli-
ﬁcation, as well as sequence variant determination with QuantStudio 12K Flex OpenArrays with TaqMan
assays. OpenArray analysis was repeated for ﬁve samples without preampliﬁcation due to an undeter-
mined genotype. In total, two CNV assays (hs00010001_cn targeting exon 9 and hs04083572_cn
targeting intron 2 of CYP2D6) and 19 sequence variants in CYP2D6 were analyzed (see Table S1 in the
supplemental material for assay details) and genotype was determined according to the cytochrome
P450 allele nomenclature website (40). Inferred phenotype was determined using the activity score
(AS) (41).
Pharmacokinetic modeling. A physiological population pharmacokinetic model was developed to
allow better extrapolation and enable identiﬁcation of pharmacokinetic parameters that cannot be
identiﬁed in classical empirical models (42). Pharmacokinetic analysis was performed by means of
nonlinear mixed effects modeling with the software NONMEM v7.3.0 and using Piraña as an interface for
NONMEM, R-statistics, and Perl Speaks Nonmem v4.6.0 (43). The covariance step in NONMEM was used
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to calculate parameter precision. To account a priori for changes in pharmacokinetics related to growth,
liver volume (VL) was calculated from total body weight and height (44). All other volumes and ﬂow
parameters were allometrically scaled to a total body weight of 70 kg, as previously proposed. The
exponents of the allometric models were ﬁxed at 0.75 and 1 for ﬂow and volume parameters, respec-
tively (45). Due to the high colinearity of age and weight, this enabled us to separately assess the impact
of age and weight on PQ pharmacokinetics. The PQ dose and measured plasma concentrations of PQ and
C-PQ were converted to their molar equivalents for this analysis. Parameter shrinkage, with a shrinkage
of 25% indicating uninformative data to estimate the parameter (46), was derived from the NONMEM
results ﬁle.
As PQ is thought to be mainly metabolized by MAO and cytochrome P450s in the liver (12), a
well-stirred liver model, a well-established model to describe hepatic metabolism of drugs, was imple-
mented to describe the physiologically plausible relationship between ﬁrst-pass and central metabolism
(47, 48). Apparent intrinsic hepatic clearances for MAO- and CYP2D6-mediated metabolism (CLint,MAO and
CLint,CYP2D6, respectively) were estimated. C-PQ was assumed to originate from the MAO-mediated
metabolism of PQ. The individual CYP2D6 intrinsic clearance (CLint,CYP2D6,i)was calculated from the
population intrinsic clearance (CLint,CYP2D6,pop) and CYP2D6 AS according to the following formula:
CLint,CYP2D6,i  AS  CLint,CYP2D6,pop. We assumed a liver plasma ﬂow (QH) of 49.5 liters/h, derived from an
adult total blood ﬂow of 90 liters/h and a plasma fraction of 55% in whole blood (hematocrit level, 45%).
The hepatic extraction (EH) was deﬁned as follows: EH  CLint/(QHP  CLInt), and the apparent MAO- and
CYP2D6-mediated hepatic clearances (CLH,MAO and CLH,CYP2D6) were calculated using the following
formula: CLH  EH  QHP.
The gradual onset of oral drug absorption was described with a chain of transition compartments, as
described earlier (49). In short, the mean absorption time (MAT) was estimated and the rate constant (ktr)
for these transition compartments was calculated using the equation ktr  (n  1)/MAT, where n equals
the number of transition compartments. The interindividual variability was modeled by means of an
exponential variance model. Throughout model building, basic goodness-of-ﬁt plots and prediction-
corrected visual predictive checks (50) were explored. Concentrations that were below the limit of
quantiﬁcation (LOQ) were retained in the analysis employing the M6 method, as proposed by Beal (51),
so the ﬁrst concentrations below the limit of quantiﬁcation were ﬁxed to 1/2 LOQ, and a ﬁxed residual
additive error of 1/2 LOQ was introduced in the model. Individuals with missing or inconclusive CYP2D6
genotype data (n  4) were retained in the model by imputing the individual activity scores using
mixture modeling, based on the frequencies observed in the study population, as proposed earlier (52).
The Bayesian imputed activity score was estimated to be 1.5 for all four children. Since ﬁxing the
individual activity scores manually resulted in better model stability and no signiﬁcant change of model
goodness-of-ﬁt, these missing activity scores were manually set to 1.5 in the ﬁnal model. The ﬁnal model
was used to obtain the empirical Bayes estimates for the AUC to inﬁnity, the Cmax, and the Tmax for both
PQ and C-PQ.
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